Almost a decade ago, the FDA approved daratumumab (Darzalex), a groundbreaking monoclonal antibody for multiple myeloma (MM). This marked a significant shift in the MM treatment landscape, ushering in an era of immunotherapies. Experts at the 2024 International Myeloma Society (IMS) Annual Meeting highlighted the evolution of these treatments, including bispecific and monoclonal antibodies, and […]